TDO2 and neoplasm: CMG017 and CB548, two dual inhibitors of IDO1 and TDO2, have been shown to potently suppress the kynurenine pathway and they showed promising anti-tumor efficacy, with favorable pharmacologic profiles, overcoming resistance to immune checkpoint inhibitors [55].